An Evidence‐based Approach to Familial Nonmedullary Thyroid Cancer: Screening, Clinical Management, and Follow‐up

Sippel, Rebecca S.; Caron, Nadine R.; Clark, Orlo H.

doi:10.1007/s00268-006-0847-1

Cited by 107 publications

(116 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, certain other studies did not confirm the difference in biological behaviors between FNMTC and SNMTC (18,19,20,21). In addition, results from several published reviews are conflicting, which have only listed major results of available studies and failed to draw conclusions based on quantitative statistical methods (9,22,23). Therefore, the exact biological characteristics and the optimal clinical approach for FNMTC are yet to be established (24,25).…”

Section: Introductionmentioning

confidence: 86%

“…Nevertheless, based on the current available evidence, it may be rational that screening individuals with relatives affected by thyroid cancer commence at an earlier age. However, there is no strict age cutoff at which screening should begin; some authors (17,22,23) recommend that screening should commence at the age of 18-20 years, or 5-10 years earlier than the youngest age of diagnosis with the family, which remains to be further elucidated. As given in Table 2, most of subgroup analyses did not show significant difference to the overall conclusion.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ENDOCRINE TUMOURS: Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis

Wang

Cheng

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: There is controversy as to whether familial nonmedullary thyroid carcinoma (FNMTC) is more aggressive than sporadic NMTC (SNMTC). The aim of the study was to evaluate the biological characteristics of patients with FNMTC by a meta-analysis. Methods: Four databases (PubMed, EMBASE, the Cochrane library databases, and the Web of Science) were searched to identify studies published before September, 2014. All original studies that compared clinical characteristics and prognosis of patients with FNMTC and SNMTC were included. The pooled effect sizes of interesting parameters were calculated by odds ratio (OR), standard mean difference (SMD), or hazard ratio (HR). Results: Twelve studies with a total of 12 741 participants were included in this analysis. FNMTC patients had an increased rate of recurrence (ORZ1.72, 95% CI: 1.34 to 2.20) and decreased disease-free survival (DFS) (HRZ1.83, 95% CI: 1.34 to 2.52) in comparison with SNMTC patients. FNMTC possessed more aggressive biological behaviors, characterized by younger age at diagnosis (SMDZK0.91, 95% CI: K1.59 to K0.22), higher risk of multifocal (ORZ1.50, 95% CI: 1.32 to 1.71), bilateral (ORZ1.29, 95% CI: 1.00 to 1.66), extrathyroidal invasion (ORZ1.20, 95% CI: 1.02 to 1.41), and lymph node metastasis (ORZ1.18, 95% CI: 1.01 to 1.38). Conclusion: FNMTC is a more aggressive disease and possesses higher recurrence rate and lower DFS. More attention and careful consideration should be paid regarding the decision about treatment for patients with FNMTC.

show abstract

Section: Introductionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

ENDOCRINE TUMOURS: Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis

Wang

Cheng

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Patients with thyroid nodules and history of total body irradiation for bone marrow transplantation or head and neck irradiation are at higher risk for malignancy (11). A family history of a first-degree relative with thyroid cancer should be carefully assessed, considering the occurrence of familial non-medullary thyroid cancer (12).…”

Section: History and Physical Examinationmentioning

confidence: 99%

Latin American Thyroid Society recommendations for the management of thyroid nodules

Camargo

Corigliano

Friguglietti

et al. 2009

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Several guidelines on diagnosis and treatment of thyroid nodules and cancer have recently been published. However, recommended practices are not always appropriate to different settings or countries. The aim of this consensus was to develop Clinical Guidelines for evaluation and management of patients with thyroid nodules applicable to Latin American countries. The panel was composed by 13 members of the Latin American Thyroid Society involved with research and management of thyroid nodules and cancer from different medical centers in Latin America. The consensus was produced based on the expert opinion of the panel with use of principles of evidence-based medicine. Following a group meeting, a first draft based on the expert opinion of the panel was elaborated and later circulated among panel members for further revision. After revision, this document was submitted to all LATS members for commentaries and considerations and finally revised and refined by the authors. The final recommendations represent state of the art on management of thyroid nodules applied to all Latin American countries. Arq Bras Endocrinol Metab. 2009;53(9):1167-75 Keywords Thyroid nodule; thyroid ultrasonography; thyroid aspiration biopsy; radioactive iodine therapy resumo Vários consensos têm sido publicados acerca do diagnóstico e do tratamento de nódulos e cân-cer da tireoide. Entretanto, as recentes recomendações nem sempre são apropriadas para diferentes regiões ou países. O objetivo deste trabalho foi oferecer uma série de recomendações para a avaliação e conduta de pacientes portadores de nódulos tireoideos aplicáveis a todos os países da América Latina. O trabalho foi realizado por um comitê composto por 13 membros da Sociedade Latino-Americana de Tireoide envolvidos com pesquisa e manejo de pacientes portadores de nódulos e carcinoma diferenciado da tireoide, de diferentes centros médicos da América Latina. As recomendações foram estabelecidas, após consenso, utilizando as opiniões especializadas de cada membro e os princípios da medicina baseada em evidência. Após a primeira reunião do grupo, um primeiro documento foi elaborado e encaminhado a todos os membros para revisão. Posteriormente, o documento foi enviado aos membros da Sociedade Latino-Americana de Tireoide para avaliação, sugestões e comentários. A versão final, elaborada após refinada revisão de todos os autores, representa o estado da arte no diagnóstico e na conduta de nódulos tireoideos, aplicáveis a todos os países da América Latina.

show abstract

“…Familial non-medullary thyroid cancer (FNMTC) accounts for w5% of all thyroid carcinomas of follicular cell origin (1,2,3,4). A vast majority of patients with FNMTC present papillary thyroid carcinoma (PTC), although benign thyroid lesions, such as multinodular goitre, are also commonly found in members of these families (2,4,5).…”

Section: Introductionmentioning

confidence: 99%

“…A vast majority of patients with FNMTC present papillary thyroid carcinoma (PTC), although benign thyroid lesions, such as multinodular goitre, are also commonly found in members of these families (2,4,5).…”

Section: Introductionmentioning

confidence: 99%

Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour

Pinto

Silva²,

Henrique

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Familial non-medullary thyroid cancer has been proposed as an aggressive clinical entity. Our aim in this study is to investigate potential distinguishing features as well as the biological and clinical aggressiveness of familial vs sporadic papillary thyroid carcinoma (PTC). We assessed clinicopathological characteristics, outcome measures and DNA ploidy. Design: A matched-case comparative study. Methods: A series of patients with familial PTC (nZ107) and two subgroups, one with three or more affected elements (nZ32) and another including index cases only (nZ61), were compared with patients with sporadic PTC (nZ107), matched by age, gender, pTNM disease extension and approximate follow-up duration. Histological variant, extrathyroidal extension, vascular invasion, tumour multifocality and bilateral growth were evaluated. Ploidy pattern was analysed in available samples by DNA flow cytometry. The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated according to the Kaplan-Meier (K-M) method. Results: No patient with familial PTC died of disease during follow-up (median, 72 months), contrarily to five patients (4.7%) (PZ0.06) with sporadic PTC (median, 90 months). There was a significantly higher tumour multifocality in familial PTC (index cases subgroup) vs sporadic PTC (PZ0.035), and a trend, in the familial PTC cohort with three or more affected elements, to show extrathyroidal extension (PZ0.054) more frequently. No difference was observed in DNA ploidy status. The K-M analyses showed no significant differences between both entities in relation to DFS or OS. Conclusion: Apart from multifocality, familial PTC appears to have similar clinical/prognostic behaviour when compared with sporadic forms of the disease.

show abstract

An Evidence‐based Approach to Familial Nonmedullary Thyroid Cancer: Screening, Clinical Management, and Follow‐up

Abstract: To date, the optimal clinical approach is yet to be established, but improved awareness and screening will permit earlier detection, more timely intervention, and hopefully improved outcomes for patients and their families.

Cited by 107 publications

References 71 publications

ENDOCRINE TUMOURS: Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis

ENDOCRINE TUMOURS: Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis

Latin American Thyroid Society recommendations for the management of thyroid nodules

Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour

Contact Info

Product

Resources

About